Littleton-based Still River Systems has signed a long-term licensing agreement with the Massachusetts Institute of Technology in Cambridge for advanced superconducting accelerator technologies.
MIT’s technology will be combined with Still River’s existing proton therapy system, known as the Monarch250, to help treat cancer.
The first Monarch250, which directs proton energy to destroy cancerous tumors, is being installed at the Siteman Cancer Center in St. Louis, Mo.
The accelerator technology that Still River is licensing was developed at MIT’s Plasma Science and Fusion Center.
Financial terms of the license were not disclosed.
